MSC 2364447

Drug Profile

MSC 2364447

Alternative Names: M-2951; MSC2364447; MSC2364447C

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Merck Serono
  • Class Small molecules
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Rheumatoid arthritis; Systemic lupus erythematosus
  • Phase I Autoimmune disorders
  • Phase Unknown Multiple sclerosis

Most Recent Events

  • 04 Jan 2017 Phase-II clinical trials in Systemic lupus erythematosus in USA (PO) (NCT02975336)
  • 29 Nov 2016 EMD Serono Research & Development Institute and Merck plan a phase II trial for Multiple sclerosis in USA and Germany (PO) (NCT02975349)
  • 23 Nov 2016 Investigation in Multiple sclerosis in USA (PO) before November 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top